THE IMPACT OF THE iPLEDGE PROGRAM ON ISOTRETININOIN FETAL EXPOSURE
Shin JI, Niu P, Wong L1, Yoshisaka MA, McCombs J1, Cheatham CT1
1USC School of Pharmacy, Los Angeles, CA, USA, 2Kaiser Permanente, Downey, CA, USA, 3Kaiser Permanente, City of Industry, CA, USA
OBJECTIVES: The objective of this retrospective cohort study is to analyze the effect of the iPLEDGE program on rates of fetal exposure to isotretinoin in females of childbearing potential (FCBP). METHODS: This study used databases from Kaiser Permanente Southern California, which includes prescription records, laboratory results, and outpatient/patient visit procedures and diagnoses. All FCBP who filled isotretinoin during the study period of March 1, 2004 to February 29, 2008 were identified. Chart review was performed to validate pregnancy in patients with positive pregnancy indicators. The analysis was performed at the treatment course-level. Treatment courses were excluded if they straddled both before and after iPLEDGE implementation on March 1, 2006. Posson regression was used to analyze the impact of iPLEDGE on the rate of fetal exposures, controlling for age, prior utilization of acne prescription medications, and other risk factors. RESULTS: There were a total of 8 fetal exposures during 2,583 treatment courses before iPLEDGE and 6 fetal exposures during 1,195 treatment courses after iPLEDGE implementation. Unadjusted fetal exposure rates increased slightly from 3.09 per 1000 treatment courses to 3.76 per 1000 treatment courses with iPLEDGE. When controlling for other factors, the rate ratio for fetal exposure after compared to before iPLEDGE implementation was 0.95 [95% CI: 0.87, 1.03] in FCBP less than 21 years of age. In FCBP greater than or equal to 21 years of age, the rate ratio was 1.46 [95% CI: 1.10, 1.94]. CONCLUSIONS: The risk of fetal exposure among treatment courses filled by younger FCBP significantly decreased by 35% after the implementation of iPLEDGE. In contrast, the risk of fetal exposure significantly increased by 46% after iPLEDGE began among treatment courses filled by older FCBP. Our results suggest that the iPLEDGE program had a differential effect on the rate of fetal exposures to isotretinoin depending on patient age group.

SENSORY SYSTEMS DISORDERS – Conceptual Papers & Research on Methods

DEVELOPMENT OF A DECISION-ANALYTIC MODEL FOR GLAUCOMA PROGRESSION USING PATIENT LEVEL DATA FROM THREE LARGE RANDOMIZED CONTROLLED TRIALS
Kymes S2, Kotak S1, Lambert D1, Stolley D1, Seigfried C1, Lee PP1, Musch D1, Fain J1, Gordon PM1
1Washington University, St. Louis, MO, USA, 2Pfizer, Inc, New York, NY, USA, 3Duke University, Durham, NC, USA, 4University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Evaluation of cost-effectiveness for chronic disease treatment requires development and validation of a model of disease progression using “real world” data. We constructed a Markov model using patient-level data from three large studies of glaucoma treatment and conducted internal validation. METHODS: Glaucoma severity and disease progression were defined clinically in terms of visual field loss expressed as mean deviation (MD) measured in decibels (dB). Patient level data for the model came from the Collaborative Initial Glaucoma Treatment Study (CIGTS n = 574), the Ocular Hypertension Treatment Study (OHTS n = 1,546), and the Advanced Glaucoma Intervention Study (AGIS n = 5,741). We used the Medical Dictionary for Regulatory Activities coding scheme (MedDRA PT) in the analysis. The model included progression over seven years. Transition probabilities for the Markov model were calculated for each combination of year and MD. The model was estimated with data from completed AGIS. This suggests that our modeling approach provides a reasonable reflection of real world progression and provides a useful tool for researchers and policy makers. Once completed, this model will provide a tool for evaluation of pressure lowering medications.

SENSORY SYSTEMS DISORDERS – Health Care Use & Policy Studies

EFFECT OF BIVALIRUDIN ON CLINICAL OUTCOMES OF STEMI PATIENTS IN AN OBSERVATIONAL DATASET
Kessler DP1
1Stanford University, Stanford, CA, USA
OBJECTIVES: Hospitals are increasingly focused on reducing patient harm associated with anticoagulant therapy. However, because treatment decisions may be based on prognosis, estimates of treatment effects obtained from observational data may suffer from “confounding by indication.” To address this concern, we used a grouped-treatment approach to determine the impact of choice of anticoagulant on the risk of severe bleeding and in-hospital death in patients undergoing percutaneous coronary intervention (PCI). METHODS: We analyzed the Premier Perspective database on Methods of January 2007 through December 2008. We included in the analysis 2585 treatment courses before iPLEDGE and 1595 treatment courses after compared to before iPLEDGE implementation was 0.45 [95%CI: 0.31, 0.67] in FCBP less than 21 years of age. In FCBP greater than or equal to 21 years of age, the rate ratio was 1.46 [95% CI: 1.10, 1.94]. CONCLUSIONS: The risk of fetal exposure among treatment courses filled by younger FCBP significantly decreased by 35% after the implementation of iPLEDGE. In contrast, the risk of fetal exposure significantly increased by 46% after iPLEDGE began among treatment courses filled by older FCBP. Our results suggest that the iPLEDGE program had a differential effect on the rate of fetal exposures to isotretinoin depending on patient age group.

SENSORY SYSTEMS DISORDERS – Health Care Use & Policy Studies

POSTMARKETING SAFETY EVALUATION OF ALISKIREN HEMIFUMARATE, A NEW MOLECULAR ENTITY
Ali AK
University of Florida, Gainesville, FL, USA
OBJECTIVES: To evaluate the safety profile of aliskiren by calculating the adjusted reporting ratios of specific adverse events. METHODS: The FDA’s Adverse Event Reporting System (AERS) data are utilized to conduct this retrospective pharmacovigilance study. Adverse event (AE) reports submitted to the AERS during the period of January 2007 through December 2008 are included in the analysis. Multi-item Gamma Poisson Shrinker (MGPS) data mining algorithm is applied to calculate the adjusted reporting ratios (ARR) of AE, which estimated by the Empiric Bayes Geometric Mean (EBGM) values and their 95% confidence intervals (95% CI). EBGM values of ≥2.0 are considered as safety signal significant for regulatory decision. Reports for aliskiren and other drugs affecting the Renin-Angiotensin-Aldosterone System (RAAS) are identified using the verbatim names for each individual class members. Reports for specific AE are identified by the utilized Preferred Terms of the Medical Dictionary for Regulatory Activities coding scheme (MedDRA PT) in the AERS. RESULTS: During the study period, a total number of 2145 reports for aliskiren are received by the AERS. Seventy four percent (1592) of these reports had valid MedDRA terms, and included in the analysis. Compared to other RAAS modulators, aliskiren was associated with the highest ARR for angioedema (EBGM 3.9, 95% CI 3.2–4.7), renal dysfunction (EBGM 3.4, 95% CI 2.6–4.5), dry cough (EBGM 11.0, 95% CI 7.8–14.2), and diarrhoea (EBGM 4.3, 95% CI 3.2–5.8). Aliskiren ranked the second after aldosterone antagonists in hyperkalemia (EBGM 7.4, 95% CI 3.4–13.0). CONCLUSIONS: Treatment with aliskiren may be associated with angioedema and renal dysfunction. Patients with signs and symptoms of angioedema should stop aliskiren and seek urgent medical help. Aliskiren should not be used by patients with risks of renal dysfunction. While additional longitudinal studies and clinical awareness is warranted, regulatory changes in product label and safety communications, e.g. dear-health care-professional letters are recommended.

THROMBOEMBOLISM

ESTIMATION OF ADVERSE EVENTS RELATED WITH MEDICARE PATIENTS WHO UNDERWENT HIP FRACTURE SURGERY AND SUFFERED VENOUS THROMBOEMBOLISM VERSUS NO VENOUS THROMBOEMBOLISM
Wang L1, Dysinger A1, Basor O1
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research / University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: To estimate mortality, re-hospitalization and bleeding 30 days after a venous thromboembolism (VTE) event in patients following hip fracture surgery and to compare the outcomes with patients without VTE. METHODS: Based on 2005–2007 national Medicare claims, all patients who underwent hip fracture surgery were identified. Thirty days follow-up event rates for patients who had a VTE event during their initial hospitalization were calculated. Events were compared between patients